Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|February 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trialRamona Erber, Oleg Gluz, Nils Brünner, et al.
Virchows Archiv : an International Journal of Pathology|November 11, 2022
Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissueClaudia Vollbrecht, Inga Hoffmann, Annika Lehmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2025
Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono TrialHans-Christian Kolberg, Johannes Schumacher, Ramona Erber, et al.
Geburtshilfe Und Frauenheilkunde|June 9, 2018
Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart DataMarius Wunderle, Gregor Olmes, Naiba Nabieva, et al.
Breast Cancer Research : BCR|January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markersLothar Häberle, Ramona Erber, Paul Gass, et al.
Geburtshilfe Und Frauenheilkunde|July 31, 2018
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among PhysiciansPaul Gass, Michael Untch, Volkmar Müller, et al.
Breast Cancer Research and Treatment|May 5, 2018
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patientsMarius Wunderle, Paul Gass, Lothar Häberle, et al.
Scientific Reports|November 2, 2024
Information mismatch in PHH3-assisted mitosis annotation leads to interpretation shifts in H&E slide analysisJonathan Ganz, Christian Marzahl, Jonas Ammeling, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating LymphocytesFranziska Würfel, Ramona Erber, Hanna Huebner, et al.
International Journal of Molecular Sciences|August 12, 2022
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World SettingRamona Erber, Miriam Angeloni, Robert Stöhr, et al.
Pageof 10